Cancer Research
Cancer is a term used to define a group of diseases in which abnormal cells divide without control, are able to invade neighboring tissues/organs and metastasize. Cancer has been characterized by six hallmarks; self sufficiency in proliferative growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replicative potential, ability to develop blood vessels (angiogenesis), and tissue invasion and metastasis.
Cancer Research Products Areas
Products for Cancer Research - Page 62
- Cat.No. Product Name Information/Activity
-
BCC4042
(S)-(+)-Ibuprofen
(S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits COX-1 and COX-2 activity with IC50s of 2.1 μM and 1.6 μM. (S)-(+)-Ibuprofen has analgesic, antiinflammatory and antipyretic effects.
-
BCC3794
Indomethacin
Indomethacin (Indometacin) is a potent and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.
-
BCC6490
Naproxen Sodium
Naproxen sodium is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
-
BCC7944
NCX 4040
287118-97-2
-
BCC6219
NCX 466
1262956-64-8
-
BCC6857
NS 398
NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (COX-2) activity, with an IC50 of 3.8 μM, and has no effect on COX-1 at 100 μM.
-
BCC3841
Piroxicam
Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.
-
BCC7111
SC 560
SC-560 is a potent and selective COX-1 inhibitor with an IC50 of 9 nM.
-
BCC5948
SC 58125
162054-19-5
-
BCC7809
SC 236
170569-86-5
